Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nobuo Seki is active.

Publication


Featured researches published by Nobuo Seki.


Journal of Clinical Investigation | 2003

Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis

Nobuchika Yamamoto; Fumihiko Sakai; Shigeyuki Kon; Junko Morimoto; Chiemi Kimura; Harumi Yamazaki; Ikuko Okazaki; Nobuo Seki; Takashi Fujii; Toshimitsu Uede

It has been shown that osteopontin (OPN) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA). However, the molecular mechanism of OPN action is yet to be elucidated. Splenic monocytes obtained from arthritic mice exhibited a significant capacity for cell migration toward thrombin-cleaved OPN but not toward full-length OPN. Migratory monocytes expressed alpha9 and alpha4 integrins. Since cleavage of OPN by thrombin exposes the cryptic epitope recognized by alpha9 and alpha4 integrins, we investigated the role of the cryptic epitope SLAYGLR in a murine RA model by using a specific antibody (M5) reacting to SLAYGLR sequence. The M5 antibody could abrogate monocyte migration toward the thrombin-cleaved form of OPN. Importantly, M5 antibody could inhibit the proliferation of synovium, bone erosion, and inflammatory cell infiltration in arthritic joints. Thus, we demonstrated that a cryptic epitope, the SLAYGLR sequence of murine OPN, is critically involved in the pathogenesis of a murine model of RA.


Bioorganic & Medicinal Chemistry Letters | 2003

Structure-Based de novo design of non-nucleoside adenosine deaminase inhibitors

Tadashi Terasaka; Isao Nakanishi; Katsuya Nakamura; Yoshiteru Eikyu; Takayoshi Kinoshita; Nobuya Nishio; Akihiro Sato; Masako Kuno; Nobuo Seki; Kazuo Sakane

We searched for non-nucleoside inhibitors of adenosine deaminase by rational structure-based de novo design and succeeded in the discovery of 1-(1-hydroxy-4-phenyl-2-butyl)imidazole-4-carboxamide (FR221647: K(i)=5.9 microM to human ADA) as a novel inhibitor with moderate activity and good pharmacokinetics compared with the known inhibitors pentostatin and EHNA.


Bioorganic & Medicinal Chemistry Letters | 1998

Synthesis and effects of novel thiazole derivatives against thrombocytopenia

Kiyoshi Tsuji; Takashi Ogino; Nobuo Seki; Masae Sawada; Yu Sudo; Fusako Nishigaki; Toshitaka Manda; Massaki Matsuo

5-(2-Pyridylsulfonyl)-2-thiazolamine (2) was effective both in mitomycin C (MMC)-induced thrombocytopenia and in an animal model of idiopathic thrombocytopenic purpura (ITP). It also suppressed the increase of autoantibodies against platelets in the ITP model and showed no blood toxicity. Chemical modification of 2 led to the discovery of more potent compounds against MMC-induced thrombocytopenia.


Hepatology | 1996

Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis.

Hidekazu Mizuhara; M Uno; Nobuo Seki; Masakatsu Yamashita; Makiko Yamaoka; Toshikazu Ogawa; Kenji Kaneda; Takashi Fujii; Hachiro Senoh; Hiromi Fujiwara


Journal of Experimental Medicine | 2000

T Cell Receptor–Induced Calcineurin Activation Regulates T Helper Type 2 Cell Development by Modifying the Interleukin 4 Receptor Signaling Complex

Masakatsu Yamashita; Makoto Katsumata; Makio Iwashima; Motoko Kimura; Chiori Shimizu; Tohru Kamata; Tahiro Shin; Nobuo Seki; Seiichi Suzuki; Masaru Taniguchi; Toshinori Nakayama


Arthritis & Rheumatism | 1989

Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis.

Yasuyuki Takai; Nobuo Seki; Hachiro Senoh; Takashi Yokota; Frank S. Lee; Toshiyuki Hamaoka; Hiromi Fujiwara


Hepatology | 1998

Strain difference in the induction of T-cell activation-associated, interferon gamma-dependent hepatic injury in mice.

Hidekazu Mizuhara; Masako Kuno; Nobuo Seki; Wen-Gong Yu; Makiko Yamaoka; Masakatsu Yamashita; Toshikazu Ogawa; Kenji Kaneda; Takashi Fujii; Hachiro Senoh; Hiromi Fujiwara


European Journal of Pharmacology | 2006

Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938.

Masako Kuno; Nobuo Seki; Susumu Tsujimoto; Isao Nakanishi; Takayoshi Kinoshita; Katsuya Nakamura; Tadashi Terasaka; Nobuya Nishio; Akihiro Sato; Takashi Fujii


Biochemistry | 2005

Structural Basis of Compound Recognition by Adenosine Deaminase

Takayoshi Kinoshita; Isao Nakanishi; Tadashi Terasaka; Masako Kuno; Nobuo Seki; Masaichi Warizaya; Hiroyoshi Matsumura; Tsuyoshi Inoue; Kazuhumi Takano; Hiroaki Adachi; Yusuke Mori; Takashi Fujii


Journal of Medicinal Chemistry | 2004

Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors

Tadashi Terasaka; Takayoshi Kinoshita; Masako Kuno; Nobuo Seki; Kohichiro Tanaka; Isao Nakanishi

Collaboration


Dive into the Nobuo Seki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge